Part,  Chapter, Paragraph

 1   II,     5.  5.  3|           European Medical Agency (EMEA), the European Commission’
 2   II,     5.  5.  3|    European Fair Trade Association~EMEA~European Medical Agency~
 3   II,     5. 15.Acr|          Orphan Medicinal Products~EMEA~European Medicines Evaluation
 4   II,     5. 15.  4|            expert Committee at the EMEA and strengthen the requirements
 5   II,     5. 15.  4|         European Medicines Agency (EMEA) to review designation applications
 6   IV,    11.Acr    |   Community Household Panel Survey~EMEA~European Medicines Agency~
 7   IV,    11.  3.  2|         European Medicines Agency (EMEA), pricing and reimbursement
 8   IV,    11.  3.  2| technologies~ ~Where possible, the EMEA will endeavour to use data
 9   IV,    11.  3.  2|           the information that the EMEA holds internally is classified
10   IV,    12.  1    |         European Medicines Agency (EMEA), pricing and reimbursement
11   IV,    12.  4    |          and their consequences.~ ~EMEA~ ~European Medicines Agency (
12   IV,    12.  4    |         European Medicines Agency (EMEA) on the development of vaccines,